Marshall Wace
ANTX icon

Marshall Wace’s AN2 Therapeutics ANTX Stock Holding History

Marshall Wace’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,700
Closed -$60.5K – 3139
2026
Q1 		$60.5K Buy
+17,700
New +$36.5K ﹤0.01% 2957
2024
Q3 		– Sell
-96,111
Closed -$207K – 2469
2024
Q2 		$207K Buy
96,111
+13,613
+17% +$32.4K ﹤0.01% 2289
2024
Q1 		$268K Sell
82,498
-254,823
-76% -$2.77M ﹤0.01% 2152
2023
Q4 		$6.91M Sell
337,321
-379,460
-53% -$6.35M 0.01% 795
2023
Q3 		$11.5M Buy
+716,781
New +$8.12M 0.02% 609

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Marshall Wace's ANTX Position: Q2 2026 in Review

Marshall Wace sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 17,700 shares — an estimated $60.5K sold.

Marshall Wace first reported a position in ANTX in Q3 2023 and held it in 5 quarters. The position peaked at $11.5M in Q3 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Marshall Wace reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 17,700 AN2 Therapeutics shares in Q2 2026, an estimated $60.5K.
  • Marshall Wace first reported a position in AN2 Therapeutics in Q3 2023 and held it in 5 quarters.
  • Marshall Wace's AN2 Therapeutics position peaked at $11.5M in Q3 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.